United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verizon

Verizon and Pfizer offer attractive dividend yields above 5%, supported by strong market positions. Both companies face challenges but have strategies in place to maintain their generous payouts.

2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the world's poorest nations at not-for-profit prices, just over two years after it launched.

Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO

W. P. Carey

W.P. Carey reduced its dividend after spinning off its office properties last year but still offers an ultra-high yield. Pfizer's been raising its dividend every year since 2009, and an unprecedented number of recently launched drugs could help it rise much further.

3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved patient population.

Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Global Markets

The benefits of Oxbryta no longer outweigh the risks, Pfizer says.

Pfizer yanks sickle-cell treatment worldwide after possible link to deaths

U.S. drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.

Pfizer withdraws sickle cell disease treatment from all markets

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickl.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer is now working on a new approach to weight, helping some patients gain weight. Is Pfizer stock a buy or a sell?

Is Pfizer Stock A Buy Or A Sell On Its New Weight-Gain Approach?

Moderna

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.

Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK

Citigroup

Comcast

Altria

Exxon Mobil

24/7 Wall St. Insights The futures market has priced in a 100% chance of a September rate cut.

5 Blue Chip Dividend Giants Passive Income Investors Can Always Count On

Carnival

Lower interest rates can make dividend stocks such as Pfizer and Verizon more attractive investment options. Falling rates can reduce companies' interest expenses, which can help Carnival better manage its high debt load.

3 Ultra-Cheap Stocks That Could Get a Boost From Fed Rate Cuts

BioNTech SE

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

Pfizer's transition from COVID revenue faces skepticism, as PFE underperformed its healthcare peers recently. Successful integration of Seagen is crucial for Pfizer's oncology portfolio, potentially lifting investor sentiment. Pfizer's cautious approach to weight loss drugs suggests success is far from certain, raising its execution risks to disrupt the market.

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high.

Pfizer Is Rising Past Covid-19

Pfizer and Moderna have seen their shares drop as their coronavirus-related tailwind ended. Yet, both companies have exciting pipelines and have earned important approvals recently.

2 Beaten-Down Stocks to Buy and Hold for a Decade

CRISPR Therapeutics

Gilead Sciences

CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.

3 Dirt Cheap Stocks to Buy Right Now

In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.

Here's Why Pfizer (PFE) Fell More Than Broader Market

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission wil.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Baxter

Bristol-Myers

CVS Health

Humana

Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025

Now that W.P. Carey is no longer in the office-leasing business, its long-term investors can rest much easier.

3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. I.

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

The healthcare giant was a star stock during the height of the pandemic thanks to its vaccine. Some Pfizer investors are hungry for an encore and showing their displeasure by shunning the stock.

Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.

Unum

Three large-cap stocks ??? AES, PFE and UNM?

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.

News for Pfizer Stock (PFE)